Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability
- Supplementary File 1:
PDF-Document (PDF, 213 KiB)
Zhang, C.; Guo, S.; Zhong, Q.; Zhang, Q.; Hossain, A.; Zheng, S.; Wang, G. Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability. Pharmaceuticals 2019, 12, 180. https://doi.org/10.3390/ph12040180
Zhang C, Guo S, Zhong Q, Zhang Q, Hossain A, Zheng S, Wang G. Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability. Pharmaceuticals. 2019; 12(4):180. https://doi.org/10.3390/ph12040180
Chicago/Turabian StyleZhang, Changde; Guo, Shanchun; Zhong, Qiu; Zhang, Qiang; Hossain, Ahamed; Zheng, Shilong; Wang, Guangdi. 2019. "Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability" Pharmaceuticals 12, no. 4: 180. https://doi.org/10.3390/ph12040180